Watchlist

Watchlist
Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc (AKTX)
Akari Therapeutics (AKTX) Investor Presentation - Slideshow
The following slide deck was published by Akari Therapeutics Plc in conjunction with this Read more …
Premarket Gainers as of 9:05 am
More news on: Blueprint Medicines, Catalyst Inc., bluebird bio, Inc., Stocks on the move, Read more …
Akari's Coversin successful in mid-stage PNH study
A Phase 2 clinical trial, COBALT , assessing Akari Therapeutics' (NASDAQ: AKTX ) lead candidate Coversin in patients with paroxysmal nocturnal hemoglobinuria (PNH) met the primary endpoint of a statistically significant reduction in LDH (lactate dehydrogenase) to within 1.8x the upper lim…
Biotech Forum Daily Digest: Our Take On MiMedx
Today's public figures can no longer write their own speeches or books, and there is some evidence that they can't read them either . - Gore Vidal The biotech sector had a decent performance in the previous week as the overall market drifted up powered by strong economic reading…
Midday Gainers / Losers
Gainers: SPPI +47% . OPTT +44% . DRIO +33% . CGG +22% . VERI +20% . PTI +19% . CREE +18% . VIVE +16% . ISIG +15% . HEBT +15% . More news on: Spectrum Pharmaceuticals, Inc., Ocean Power Technologies, Inc., DarioHealth Corp., Stocks on the move, Read more…
Akari prices ADS offering at $5; shares down 24%
Akari Therapeutics ( AKTX -23.8% ) prices its public offering of 3.48M American Depositary Shares (ADSs) at $5 per ADS. Underwriters over-allotment is an additional 522K ADSs. Closing date is October 20. More news on: Akari Therapeutics Plc, Healthcare stocks news, Stocks on the move, …
3 Potential Long Ideas From Today's Relative Volume Scan
Running daily or weekly scans (depending on available time) is a great way to find current and future winners in the healthcare sector and other areas of the stock market. Whether looking at relative volume, insider buying, stocks making new highs, breaks above the 50-day moving average or oth…
Midday Gainers / Losers
Gainers: LBIX +84% . CASI +71% . SRNE +37% . WPCS +37% . AKTX +34% . RGSE +34% . AMMA +23% . HMNY +22% . FRSX +19% . PVG +20% . More news on: Leading Brands Inc, CASI Pharmaceuticals, Sorrento Therapeutics, Inc., Stocks on the move, Read more …
Akari reports three additional enrollees in mid-stage study of Coversin in PNH; update in December at ASH
Akari Therapeutics (NASDAQ: AKTX ) announces the enrollment of three new patients in the Phase 2 COBALT study assessing lead candidate Coversin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). More news on: Akari Therapeutics Plc, Healthcare stocks news, Read more … ...
An In-Depth Look At Alexion's Competition And Upcoming Catalysts
Alexion Pharmaceuticals, Inc. ( ALXN ) is a biopharmaceutical company with three marketed drugs, a promising pipeline member in ALXN1210, and a market cap of over $31 billion. ALXNs major source of revenue, however, a drug called eculizumab (marketed as Soliris), may face competition i…
Akari Therapeutics: What's Next For This 'Busted IPO'?
We are all subject to the fates. But we must act as if we are not, or die of despair. - Philip Pullman Today we look at a small-cap concern I received a question on from a Biotech Forum member last week that I had not previously researched. It is being posted here as the concern …
Akari Therapeutics Plc (AKTX)